<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The author presents an account of contemporary and perspective indications of the therapeutic use of recombinant human erythropoietin (r-HuEPO) </plain></SENT>
<SENT sid="1" pm="."><plain>He discusses the role of endogenous erythropoietin in the pathogenesis of hypoproliferative <z:hpo ids='HP_0001903'>anaemias</z:hpo> (due to its shortage or inadequate effect) and classification of these conditions as a starting point of expedient therapeutic use of r-HuEPO in clinical practice </plain></SENT>
<SENT sid="2" pm="."><plain>More detailed attention is paid in particular to the problem of treatment of <z:hpo ids='HP_0001903'>anaemia</z:hpo> in patients with <z:hpo ids='HP_0003774'>chronic renal failure</z:hpo>, <z:hpo ids='HP_0001903'>anaemia</z:hpo> in <z:hpo ids='HP_0011010'>chronic</z:hpo> inflammatory and malignant diseases, in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The author mentions also the use of r-HuEPO in preoperative preparation, in the programme of autotransfusions and its perspective use in transfusiology </plain></SENT>
</text></document>